3 Einträge |
Seite 1 / 1
![]() |
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
PMID: 29146401 |
Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study. |
O'Connor Juan M, Öhler L, Scheithauer W, Metges JP, Dourthe LM, de Groot Jan W, Thaler J, Yeh KH, Lin JK, Falcone A, Punt CJA, Kalinovsky J, Fiala-Buskies S, Cervantes A, Petersen LN, Ducreux M |
Annals of oncology : official journal of the European Society for Medical Oncology. pii: S0923-7534(19)66204-6. doi: 10.1093/annonc/mdx263.024 |
PMID: 32135658 |
A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE. |
Payne H, Robinson A, Rappe B, Hilman S, De Giorgi U, Joniau S, Bordonaro R, Mallick S, Dourthe LM, Flores MM, Gumà J, Baron B, Duran A, Pranzo A, Serikoff A, Mott D, Herdman M, Pavesi M, De Santis M |
International journal of cancer. 2021 Oct 14. doi: 10.1002/ijc.33845 |
PMID: 34648657 |
3 Einträge |
Seite 1 / 1
![]() |